Physicians should not prescribe ADD drugs to healthy people

Physicians in Canada should consider refusing to prescribe cognitive enhancement medications—also used to treat attention deficit disorder (ADD)—to healthy patients, states an analysis article in CMAJ (Canadian Medical Association Journal). Lack of evidence for benefits and possibility of harm, limited health care resources and professional integrity of physicians are reasons why this use is not acceptable.

Prescription stimulants such as methylphenidate and dextroamphetamine are often used by people for "cognitive enhancement" to increase focus, concentration and memory. Because these drugs are available in Canada by prescription only, people must request them from their doctors.

"Physicians are important stakeholders in this debate, given the risks and regulations of prescription drugs and the potential for requests from patients for cognitive enhancers," writes Dr. Eric Racine, Institut de recherches cliniques de Montréal and Université de Montréal, with coauthors.

People take prescription stimulants to perform better in school or at work. Prevalence rates of cognitive enhancer use by university students ranges from 1% to 11% in some studies. Risks to taking stimulants include cardiovascular harm, dependence and psychosis. Current evidence has not shown that the desired benefits of enhanced are achieved with these substances.

"With uncertain benefits and clear harms, it is difficult to support the notion that physicians should prescribe a medication to a healthy individual for enhancement purposes," adds Dr. Racine with Cynthia Forlini, two coauthors of the paper.

Because physicians in Canada provide prescriptions through a publicly funded health care system with expanding demands for care, prescribing cognitive enhancers may not be an appropriate use of resources.

"Given the current state of limited evidence on medical, scientific, social and ethical aspects of cognitive enhancement, we call for greater attention to its appropriateness within existing Canadian health care systems," the authors conclude.

More information: Paper: www.cmaj.ca/lookup/doi/10.1503/cmaj.121508

add to favorites email to friend print save as pdf

Related Stories

Time to address stimulant abuse on our campuses

Sep 06, 2011

Universities and colleges need to do more to protect young adults from the dangers of illicit stimulant use and to educate them about harms, argue the authors of an editorial in CMAJ (Canadian Medical Association Journal).

Prescriptions for teens and young adults on the rise

Nov 29, 2010

Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have ...

Recommended for you

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments